IL117116A0 - A medical composition for the in vivo transfection and expression of exogenes - Google Patents
A medical composition for the in vivo transfection and expression of exogenesInfo
- Publication number
- IL117116A0 IL117116A0 IL11711696A IL11711696A IL117116A0 IL 117116 A0 IL117116 A0 IL 117116A0 IL 11711696 A IL11711696 A IL 11711696A IL 11711696 A IL11711696 A IL 11711696A IL 117116 A0 IL117116 A0 IL 117116A0
- Authority
- IL
- Israel
- Prior art keywords
- exogenes
- expression
- medical composition
- vivo transfection
- vivo
- Prior art date
Links
- 238000001727 in vivo Methods 0.000 title abstract 2
- 238000001890 transfection Methods 0.000 title abstract 2
- 230000003721 exogen phase Effects 0.000 title 1
- 108020004511 Recombinant DNA Proteins 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000002480 immunoprotective effect Effects 0.000 abstract 1
- 229940125721 immunosuppressive agent Drugs 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 241000701161 unidentified adenovirus Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9501662A FR2730411B1 (fr) | 1995-02-14 | 1995-02-14 | Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL117116A0 true IL117116A0 (en) | 1996-06-18 |
Family
ID=9476106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL11711696A IL117116A0 (en) | 1995-02-14 | 1996-02-12 | A medical composition for the in vivo transfection and expression of exogenes |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20030004091A1 (da) |
| EP (1) | EP0809516B1 (da) |
| JP (1) | JPH11500430A (da) |
| KR (1) | KR100402540B1 (da) |
| AT (1) | ATE204481T1 (da) |
| AU (1) | AU717218B2 (da) |
| BR (1) | BR9607310A (da) |
| CA (1) | CA2211039C (da) |
| CZ (1) | CZ258197A3 (da) |
| DE (1) | DE69614668T2 (da) |
| DK (1) | DK0809516T3 (da) |
| ES (1) | ES2163612T3 (da) |
| FI (1) | FI119176B (da) |
| FR (1) | FR2730411B1 (da) |
| GR (1) | GR3036438T3 (da) |
| HU (1) | HU222991B1 (da) |
| IL (1) | IL117116A0 (da) |
| MX (1) | MX9706017A (da) |
| NO (1) | NO320072B1 (da) |
| PT (1) | PT809516E (da) |
| SK (1) | SK282235B6 (da) |
| WO (1) | WO1996025177A1 (da) |
| ZA (1) | ZA961161B (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6451571B1 (en) | 1994-05-02 | 2002-09-17 | University Of Washington | Thymidine kinase mutants |
| WO1998008539A1 (en) * | 1996-08-26 | 1998-03-05 | Chiron Corporation | Postinfection human immunodeficiency virus (hiv) vaccination therapy |
| WO1999023229A1 (en) | 1997-10-30 | 1999-05-14 | Cornell Research Foundation, Inc. | A method of inhibiting an immune response to a recombinant vector |
| WO2000039304A2 (en) | 1998-12-31 | 2000-07-06 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| AU2221600A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
| WO2000074688A1 (en) * | 1999-06-08 | 2000-12-14 | The Children's Hospital Of Philadelphia | Methods for preventing formation of inhibitory antibodies in the setting of gene therapy |
| FR2799472B1 (fr) * | 1999-10-07 | 2004-07-16 | Aventis Pharma Sa | Preparation d'adenovirus recombinants et de banques adenovirales |
| KR100840816B1 (ko) | 2000-05-12 | 2008-06-23 | 젠자임 코포레이션 | ＴＮＦ-α시그널링의 조절물질 |
| EP2412242A3 (en) | 2001-07-05 | 2012-06-13 | Novartis Vaccines and Diagnostics, Inc. | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| US20030170614A1 (en) | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
| US7569217B2 (en) * | 2001-09-24 | 2009-08-04 | University Of Saskatchewan | Porcine adenovirus E1 and E4 regions |
| EP1432447A2 (en) * | 2001-09-27 | 2004-06-30 | The Board Of Regents, The University Of Texas System | Combined compositions and methods for tumor vasculature coagulation and treatment |
| US7687530B2 (en) * | 2002-11-21 | 2010-03-30 | Genzyme Corporation | Inhibition of chronic tissue transplant rejection |
| AU2003291143A1 (en) * | 2002-11-21 | 2004-06-18 | Genzyme Corporation | Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance |
| AU2005213449A1 (en) * | 2004-02-04 | 2005-08-25 | The La Jolla Institute For Allergy And Immunology | Anti-CD3 and antigen-specific immunotherapy to treat autoimmunity |
| WO2008013918A2 (en) * | 2006-07-26 | 2008-01-31 | Myelin Repair Foundation, Inc. | Cell cycle regulation and differentiation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994016065A1 (en) * | 1992-12-31 | 1994-07-21 | Exemplar Corporation | Producing cells for transplantation to reduce host rejection and resulting cells |
| AU5965294A (en) * | 1993-01-08 | 1994-08-15 | Exemplar Corporation | An (in vitro)/(in vivo) method for identifying anti-neoplastic drugs |
| FR2705686B1 (fr) * | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| US5872154A (en) * | 1995-02-24 | 1999-02-16 | The Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant adenovirus |
-
1995
- 1995-02-14 FR FR9501662A patent/FR2730411B1/fr not_active Expired - Fee Related
-
1996
- 1996-02-12 DK DK96903080T patent/DK0809516T3/da active
- 1996-02-12 PT PT96903080T patent/PT809516E/pt unknown
- 1996-02-12 JP JP8524707A patent/JPH11500430A/ja not_active Ceased
- 1996-02-12 MX MX9706017A patent/MX9706017A/es unknown
- 1996-02-12 SK SK1108-97A patent/SK282235B6/sk not_active IP Right Cessation
- 1996-02-12 DE DE69614668T patent/DE69614668T2/de not_active Expired - Lifetime
- 1996-02-12 WO PCT/FR1996/000218 patent/WO1996025177A1/fr not_active Ceased
- 1996-02-12 AU AU47238/96A patent/AU717218B2/en not_active Ceased
- 1996-02-12 BR BR9607310A patent/BR9607310A/pt not_active Application Discontinuation
- 1996-02-12 CZ CZ972581A patent/CZ258197A3/cs unknown
- 1996-02-12 IL IL11711696A patent/IL117116A0/xx unknown
- 1996-02-12 AT AT96903080T patent/ATE204481T1/de active
- 1996-02-12 CA CA2211039A patent/CA2211039C/fr not_active Expired - Fee Related
- 1996-02-12 EP EP96903080A patent/EP0809516B1/fr not_active Expired - Lifetime
- 1996-02-12 KR KR1019970705594A patent/KR100402540B1/ko not_active Expired - Fee Related
- 1996-02-12 US US08/894,246 patent/US20030004091A1/en not_active Abandoned
- 1996-02-12 ES ES96903080T patent/ES2163612T3/es not_active Expired - Lifetime
- 1996-02-12 HU HU9800635A patent/HU222991B1/hu not_active IP Right Cessation
- 1996-02-13 ZA ZA961161A patent/ZA961161B/xx unknown
-
1997
- 1997-08-13 NO NO19973724A patent/NO320072B1/no not_active IP Right Cessation
- 1997-08-13 FI FI973323A patent/FI119176B/fi not_active IP Right Cessation
-
2001
- 2001-08-23 GR GR20010400947T patent/GR3036438T3/el unknown
-
2004
- 2004-04-14 US US10/823,682 patent/US20040265276A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL117116A0 (en) | A medical composition for the in vivo transfection and expression of exogenes | |
| UA66417C2 (en) | Recombinant adenovirus affecting canines, pharmaceutical composition | |
| GR3032744T3 (en) | Surface expression of enzyme in gene directed prodrug therapy | |
| IL111734A0 (en) | Compositions for the preparation of in vivo therapeutic products | |
| CY2396B1 (en) | Pharmaceutical composition of fenofibrate with high biological availability and method for preparingsame. | |
| AU4882296A (en) | DNA molecules, preparation and use in gene therapy | |
| AU4718297A (en) | Improvements in or relating to diagnostic/therapeutic agents | |
| DE69835201D1 (en) | Neoglycoproteine | |
| AU9676198A (en) | Drug delivery and gene therapy delivery system | |
| AU5788096A (en) | Plasmid for delivery of nucleic acids to cells and methods of use | |
| GB2314022B (en) | Blending medical composition with sustained medicament releasability and process for preparing the same | |
| EP0766974A3 (en) | Blood reservoir, blood delivery instrument, and blood delivery apparatus | |
| MX9801264A (es) | Control de la expresion del gen de cd44 para uso terapeutico. | |
| AU4378996A (en) | Cell compositions for use in transplantation and ex vivo gene therapy | |
| HUP9900317A3 (en) | Pharmaceutical composition useful for nucleic acid transfection, and use thereof | |
| AU3698297A (en) | Compositions containing at least one nucleic acid and their applications in the biomedical field, particularly in gene therapy | |
| GB9601640D0 (en) | Ligand directed enzyme prodrug therapy | |
| AU6346898A (en) | Gene therapy using bone marrow transplants transfected with therapeutic genes under the control of tissue-specific promoters | |
| AU2001258638A1 (en) | Methods for identifying modulators of the interaction between lap (latency associated peptide) and intergrin alpha.v.beta.3 and medical use thereof | |
| HUP9904201A3 (en) | Transfecting composition usable in gene therapy combining a recombinant virus incorporating an exogenous nucleic acid, a non-viral and non-plasmid transfecting agent | |
| AU2114899A (en) | Nucleotide expression systems with reduced immunogenicity for use in gene therapy | |
| MX9706569A (es) | Virus recombinantes que expresan la lecitina-colesterol aciltransferasa y sus usos en terapia genica. | |
| ZA971086B (en) | New thymidine kinase variants, corresponding nucleic acid sequences and their use in gene therapy. | |
| GB9724840D0 (en) | Reduced blood cholesterol | |
| MX9800697A (es) | Uso de glicosidos de calendula para el tratamiento de psoriasis. |